MarketPeel
Insider Trading Intelligence
Pricing
…
KB

Khoso Baluch

CRMD
CHIEF EXECUTIVE OFFICER · CORMEDIX INC. · CIK 0001686223
FILING MIX · LIFETIME85%/15%
BUYS
23
SELLS
4
TOTAL VALUE
$628.4K
COMPANIES
3
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
375,044
AVG SELL PX
$1.98
TRADE KIND
SHOWING 27 / 27
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
8 backtested trades · 8 horizons · 8 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Khoso Baluch, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d8+62.50%+10.68%+0.52%+10.15%+10.61%—
14d8+75.00%+5.26%+2.02%+3.24%+8.09%—
30d8+75.00%+0.57%+4.75%-4.18%+1.98%—
60d8+75.00%+1.21%+6.70%-5.52%+14.29%—
90d8+62.50%-0.96%+10.18%-11.13%-15.22%—
180d8(1 pending)+42.86%+10.11%+15.04%-4.93%-34.79%—
1y8(3 pending)+60.00%+23.32%+33.47%-10.15%-82.36%—
2y8(4 pending)+25.00%-17.79%+54.11%-71.90%-87.11%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CRMD · 320,000 shares · as of Jan 11, 2021
080,000160,000240,000320,0002021SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 23 buys / 4 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
203——2,528Jun 26, 2026Jun 30, 2026 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
SALE
203——5,249Jun 26, 2026Jun 30, 2026 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
2,269$2.54$5.8K2,325Mar 31, 2026Apr 1, 2026 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
100,000——100,000Oct 1, 2025Oct 3, 2025 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
300,000——300,000Oct 1, 2025Oct 3, 2025 ↗View →
LGVN
LONGEVERON INC.
PURCHASE
29,415——29,415Aug 11, 2025Aug 13, 2025 ↗View →
LGVN
LONGEVERON INC.
PURCHASE
11,766——52,516Aug 11, 2025Aug 13, 2025 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
175,299——206,505Jul 24, 2025Jul 28, 2025 ↗View →
LGVN
LONGEVERON INC.
PURCHASEGRANT
Stock grant
17,000——40,750Jul 15, 2025Jul 17, 2025 ↗View →
LGVN
LONGEVERON INC.
SALE
1,250$2.07$2.6K23,750Dec 2, 2024Dec 4, 2024 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
31,206——36,275Sep 3, 2024Sep 18, 2025 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
31,206——31,206Sep 3, 2024Sep 18, 2024 ↗View →
LGVN
LONGEVERON INC.
PURCHASEGRANT
Stock grant
23,500——38,375Aug 15, 2024Aug 19, 2024 ↗View →
LGVN
LONGEVERON INC.
SALE
125$1.06$13314,875Jun 9, 2024Jun 11, 2024 ↗View →
LGVN
LONGEVERON INC.
PURCHASE
8,322$1.43$11.9K15,000Dec 29, 2023Jan 2, 2024 ↗View →
LGVN
LONGEVERON INC.
PURCHASE
1,678$1.40$2.3K6,678Dec 28, 2023Jan 2, 2024 ↗View →
LGVN
LONGEVERON INC.
PURCHASEGRANT
Stock grant
12,000——12,000Dec 21, 2023Dec 26, 2023 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
101,365——101,365Jun 27, 2023Jul 24, 2023 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
15,455——27,955Jun 27, 2023Jul 24, 2023 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
SALE
15,455——0Jun 27, 2023Jul 24, 2023 ↗View →
LGVN
LONGEVERON INC.
PURCHASEGRANT
Stock grant
5,000——5,000Jun 9, 2023Jun 12, 2023 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,500$0.80$10.0K12,500Feb 9, 2023Feb 10, 2023 ↗View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
19,091——19,091Jul 12, 2022Jul 14, 2022 ↗View →
CRMD
CORMEDIX INC.
PURCHASEGRANT
Stock grant
320,000——320,000Jan 11, 2021Jan 13, 2021 ↗View →
CRMD
CORMEDIX INC.
PURCHASE
Chief Executive Officer
4,830$4.14$20.0K60,905Aug 13, 2020Aug 17, 2020 ↗View →
CRMD
CORMEDIX INC.
PURCHASE
Chief Executive Officer
3,500$2.61$9.1K56,075Mar 18, 2020Mar 18, 2020 ↗View →
CRMD
CORMEDIX INC.
PURCHASEGRANT
Stock grant
100,630$5.63$566.5K100,630Feb 25, 2020Feb 27, 2020 ↗View →
Other insiders · CRMD
Loading peer insiders…
About this filer
CIK 0001686223
ROLE
Chief Executive Officer
PRIMARY
CRMD
COMPANIES
3
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001686223DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback